Who
Kamil Ali-Jackson
Director
Company insider
Files Form 4 as: Director, Rigel Pharmaceuticals; Director, PDS Biotechnology; Chief Legal Officer, Aclaris Therapeutics.
In numbers
- Trades disclosed
- 139
- Buys
- 1
- Sells
- 16
- Bought
- $100K
- Sold
- $3.6M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 13 Oct 2015
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $88K2,500 at $35.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $88K2,500 at $35.00 | filing |
| 26 May 2026filed 28 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $73K2,500 at $29.17 | filing |
| 26 May 2026filed 28 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Sold | $73K2,500 at $29.17 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 15 May 2026filed 19 May 2026 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —5,750 at $0.00 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 12 Jan 2026filed 3 Mar 2026 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,876 at $0.00 | filing |
| 11 Jun 2025filed 11 Jun 2025 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —22,700 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —3,000 at $0.00 | filing |
| 23 May 2025filed 28 May 2025 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —2,500 at $0.00 | filing |
| 24 Jun 2024filed 25 Jun 2024 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 25 May 2024filed 29 May 2024 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 14 Jul 2023filed 17 Jul 2023 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 26 May 2023filed 12 Jul 2023 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 May 2023filed 12 Jul 2023 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 28 Jun 2022filed 29 Jun 2022 | PDSB PDS Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
| 20 May 2022filed 23 May 2022 | RIGL Rigel Pharmaceuticalsoption or derivative · Pharmaceuticals | SEC FORM 4 Code A | —22,500 at $0.00 | filing |
| 20 May 2022filed 23 May 2022 | RIGL Rigel PharmaceuticalsPharmaceuticals | SEC FORM 4 Code A | —18,750 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.